EGFR-话题@MedSci

#EGFR#

4篇内容 | 3160人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237600, encodeId=2cee223e600de, content=<a href='/topic/show?id=31c58261992' target=_blank style='color:#2F92EE;'>#肾移植#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a>, objectTitle=CKJ：基于eGFR变化预测肾移植患者长期移植物存活及死亡风险的有效性, objectType=article, longId=851651, objectId=3cf8851651cf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240925/1727244385647_8538692.jpg, objectUrl=/article/show_article.do?id=3cf8851651cf, replyNumber=0, likeNumber=48, createdTime=2024-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3cf8851651cf, moduleTitle=CKJ：基于eGFR变化预测肾移植患者长期移植物存活及死亡风险的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf8851651cf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230591, encodeId=49ff223059157, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a> <a href='/topic/show?id=d179116642cc' target=_blank style='color:#2F92EE;'>#贝莫苏拜单抗#</a>, objectTitle=STTT | 新方案：贝莫苏拜单抗联合安罗替尼显著延长EGFR阳性晚期NSCLC患者的PFS, objectType=article, longId=846806, objectId=f312846806bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401012/1728740013527_6145188.jpg, objectUrl=/article/show_article.do?id=f312846806bf, replyNumber=0, likeNumber=67, createdTime=2024-10-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f312846806bf, moduleTitle=STTT | 新方案：贝莫苏拜单抗联合安罗替尼显著延长EGFR阳性晚期NSCLC患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f312846806bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2217555, encodeId=a452221e55516, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失, objectType=article, longId=836883, objectId=8897836883f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240701/1719800269608_92910.png, objectUrl=/article/show_article.do?id=8897836883f2, replyNumber=0, likeNumber=106, createdTime=2024-07-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8897836883f2, moduleTitle=为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8897836883f2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2217275, encodeId=54c7221e27527, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a> <a href='/topic/show?id=51c91669428' target=_blank style='color:#2F92EE;'>#SRS#</a>, objectTitle=JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势, objectType=article, longId=836556, objectId=82d1836556ec, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240728/1722134116965_6145188.png, objectUrl=/article/show_article.do?id=82d1836556ec, replyNumber=0, likeNumber=114, createdTime=2024-07-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=82d1836556ec, moduleTitle=JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d1836556ec)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216854, encodeId=e02822168543e, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a> <a href='/topic/show?id=33eb11e10878' target=_blank style='color:#2F92EE;'>#奥希替尼耐药#</a> <a href='/topic/show?id=016811e1092d' target=_blank style='color:#2F92EE;'>#C797S突变#</a>, objectTitle=贝家智汇 | 徐龙教授：突破三代耐药难题，埃克替尼为EGFR 19del/C797S突变NSCLC治疗带来新选择, objectType=article, longId=836157, objectId=a9a983615e95, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719326150597_5579292.jpg, objectUrl=/article/show_article.do?id=a9a983615e95, replyNumber=0, likeNumber=94, createdTime=2024-07-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a9a983615e95, moduleTitle=贝家智汇 | 徐龙教授：突破三代耐药难题，埃克替尼为EGFR 19del/C797S突变NSCLC治疗带来新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a983615e95)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214253, encodeId=db09221425334, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗, objectType=article, longId=833763, objectId=21b4833e6364, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240710/1720582603558_1608702.jpg, objectUrl=/article/show_article.do?id=21b4833e6364, replyNumber=0, likeNumber=120, createdTime=2024-07-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=21b4833e6364, moduleTitle=李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21b4833e6364)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213472, encodeId=94d122134e289, content=<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃万妥单抗#</a> <a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉泽替尼#</a>, objectTitle=Ann. Oncol | 埃万妥单抗-拉泽替尼联合疗法有效克服 EGFR 突变晚期非小细胞肺癌高风险特征的预后影响, objectType=article, longId=832914, objectId=0cf2832914e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1720014438849_6145188.png, objectUrl=/article/show_article.do?id=0cf2832914e4, replyNumber=0, likeNumber=103, createdTime=2024-07-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0cf2832914e4, moduleTitle=Ann. Oncol | 埃万妥单抗-拉泽替尼联合疗法有效克服 EGFR 突变晚期非小细胞肺癌高风险特征的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cf2832914e4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212299, encodeId=b44822122992b, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, objectTitle=注意了，肺癌EGFR和TP53基因双突变且基因组加倍靶向药疗效差，需要早准备替代治疗！, objectType=article, longId=831898, objectId=af9283189816, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719623433682_5579292.png, objectUrl=/article/show_article.do?id=af9283189816, replyNumber=0, likeNumber=116, createdTime=2024-06-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=af9283189816, moduleTitle=注意了，肺癌EGFR和TP53基因双突变且基因组加倍靶向药疗效差，需要早准备替代治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9283189816)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205450, encodeId=d28e220545058, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a>, objectTitle=JAMA子刊：难治性ctDNA RAS/BRAF野生型转移性结直肠癌获益于抗EGFR再挑战治疗, objectType=article, longId=826423, objectId=e22e82642391, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716044161853_5579292.jpg, objectUrl=/article/show_article.do?id=e22e82642391, replyNumber=0, likeNumber=92, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e22e82642391, moduleTitle=JAMA子刊：难治性ctDNA RAS/BRAF野生型转移性结直肠癌获益于抗EGFR再挑战治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e22e82642391)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205077, encodeId=e91622050e7fd, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a>, objectTitle=好事情，EGFR阳性肺癌靶向药耐药后，免疫的“冷”肿瘤“变”热肿瘤！, objectType=article, longId=825217, objectId=864882521eae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240516/1715850737875_5579292.png, objectUrl=/article/show_article.do?id=864882521eae, replyNumber=0, likeNumber=107, createdTime=2024-05-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=864882521eae, moduleTitle=好事情，EGFR阳性肺癌靶向药耐药后，免疫的“冷”肿瘤“变”热肿瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864882521eae)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203763, encodeId=49302203e635b, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a>, objectTitle=确诊肺癌且EGFR或ALK基因突变，什么时候用靶向药治疗效果好?, objectType=article, longId=825058, objectId=dc2a82505840, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240509/1715264765962_5579292.jpg, objectUrl=/article/show_article.do?id=dc2a82505840, replyNumber=0, likeNumber=120, createdTime=2024-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dc2a82505840, moduleTitle=确诊肺癌且EGFR或ALK基因突变，什么时候用靶向药治疗效果好?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc2a82505840)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200611, encodeId=096b22006119a, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=JTO重磅：肺癌EGFR少见突变最全新整理，一二三代EGFR-TKI如何选择, objectType=article, longId=823395, objectId=daea823395ee, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, objectUrl=/article/show_article.do?id=daea823395ee, replyNumber=0, likeNumber=171, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=daea823395ee, moduleTitle=JTO重磅：肺癌EGFR少见突变最全新整理，一二三代EGFR-TKI如何选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daea823395ee)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195212, encodeId=4de42195212cf, content=<a href='/topic/show?id=01858406438' target=_blank style='color:#2F92EE;'>#胶质母细胞瘤#</a> <a href='/topic/show?id=37ea11264e47' target=_blank style='color:#2F92EE;'>#CAR-T 细胞疗法#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=e61311190563' target=_blank style='color:#2F92EE;'>#IL13RΑ2#</a>, objectTitle=Nat Med：初步临床试验表明鞘内注射靶向EGFR和IL13Rα2的双靶点CAR-T细胞有望治疗复发性胶质母细胞瘤, objectType=article, longId=817822, objectId=f49281e82214, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240323/1711193821858_2185383.png, objectUrl=/article/show_article.do?id=f49281e82214, replyNumber=0, likeNumber=98, createdTime=2024-03-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189037, encodeId=4be9218903ee1, content=<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a> <a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>, objectTitle=Science：新研究揭示肺腺癌向小细胞肺癌转变机制, objectType=article, longId=814188, objectId=84fc814188e3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240222/1708556081598_2185383.png, objectUrl=/article/show_article.do?id=84fc814188e3, replyNumber=0, likeNumber=93, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185694, encodeId=ca722185694e5, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a> <a href='/topic/show?id=d72e11086338' target=_blank style='color:#2F92EE;'>#E746del#</a>, objectTitle=“绘”解读真报告丨国内首例报道！肺癌检出EGFR E746del，是否可以使用EGFR-TKI靶向治疗？, objectType=article, longId=812019, objectId=e3c681201964, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=e3c681201964, replyNumber=0, likeNumber=142, createdTime=2024-02-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=e3c681201964, moduleTitle=“绘”解读真报告丨国内首例报道！肺癌检出EGFR E746del，是否可以使用EGFR-TKI靶向治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3c681201964)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185733, encodeId=96e22185e33d4, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=JTO真实世界9万+样本：奥希替尼耐药NSCLC的基因突变谱和后续治疗结局, objectType=article, longId=812168, objectId=6d498121683f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-team-discussing-together-in-the-hallway-PJWSSDB.jpg, objectUrl=/article/show_article.do?id=6d498121683f, replyNumber=0, likeNumber=127, createdTime=2024-02-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=6d498121683f, moduleTitle=JTO真实世界9万+样本：奥希替尼耐药NSCLC的基因突变谱和后续治疗结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d498121683f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184890, encodeId=6c80218489060, content=<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a> <a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=234613893a4' target=_blank style='color:#2F92EE;'>#PD-1#</a>, objectTitle=最新报道：EGFR靶向药耐药之后，打化疗的基础上加上PD-1并不能延迟病情进展！, objectType=article, longId=810076, objectId=a1b58100e653, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-team-discussing-together-in-the-hallway-PJWSSDB.jpg, objectUrl=/article/show_article.do?id=a1b58100e653, replyNumber=0, likeNumber=116, createdTime=2024-01-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a1b58100e653, moduleTitle=最新报道：EGFR靶向药耐药之后，打化疗的基础上加上PD-1并不能延迟病情进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b58100e653)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183024, encodeId=465821830245b, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>, objectTitle=JCO：阿替利珠单抗联合贝伐珠单抗联合化疗治疗 EGFR 或 ALK 突变非小细胞肺癌患者的 III 期随机研究 , objectType=article, longId=810273, objectId=b8da8102e328, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240120/1705761668295_6145188.png, objectUrl=/article/show_article.do?id=b8da8102e328, replyNumber=0, likeNumber=91, createdTime=2024-01-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b8da8102e328, moduleTitle=JCO：阿替利珠单抗联合贝伐珠单抗联合化疗治疗 EGFR 或 ALK 突变非小细胞肺癌患者的 III 期随机研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8da8102e328)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182845, encodeId=c17821828455e, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=奥西替尼联合或不联合化疗治疗EGFR突变的晚期非小细胞肺癌的中枢神经系统疗效, objectType=article, longId=810136, objectId=e8988101364e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240119/1705679090295_6145188.png, objectUrl=/article/show_article.do?id=e8988101364e, replyNumber=0, likeNumber=105, createdTime=2024-01-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e8988101364e, moduleTitle=奥西替尼联合或不联合化疗治疗EGFR突变的晚期非小细胞肺癌的中枢神经系统疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8988101364e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174227, encodeId=263021e422787, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=011941548ad' target=_blank style='color:#2F92EE;'>#埃克替尼#</a> <a href='/topic/show?id=c0501084e91d' target=_blank style='color:#2F92EE;'>#贝福替尼#</a>, objectTitle=贝家讲坛 | 聚焦脑转移与共突变人群，原研EGFR-TKI贝福替尼与埃克替尼先「卷」为敬, objectType=article, longId=804440, objectId=cc00804440fd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668021554762_4754896.jpeg, objectUrl=/article/show_article.do?id=cc00804440fd, replyNumber=0, likeNumber=153, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cc00804440fd, moduleTitle=贝家讲坛 | 聚焦脑转移与共突变人群，原研EGFR-TKI贝福替尼与埃克替尼先「卷」为敬, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc00804440fd)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

EGFR

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肾移植# #EGFR#

CKJ：基于eGFR变化预测肾移植患者长期移植物存活及死亡风险的有效性

2024-11-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #EGFR# #安罗替尼# #贝莫苏拜单抗#

STTT | 新方案：贝莫苏拜单抗联合安罗替尼显著延长EGFR阳性晚期NSCLC患者的PFS

2024-10-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #靶向治疗# #ROS1#

为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失

2024-07-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #ALK# #EGFR# #免疫检查点抑制剂# #SRS#

JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势

2024-07-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #埃克替尼# #奥希替尼耐药# #C797S突变#

贝家智汇 | 徐龙教授：突破三代耐药难题，埃克替尼为EGFR 19del/C797S突变NSCLC治疗带来新选择

2024-07-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #阿法替尼# #奥希替尼#

李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗

2024-07-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#EGFR# #埃万妥单抗# #拉泽替尼#

Ann. Oncol | 埃万妥单抗-拉泽替尼联合疗法有效克服 EGFR 突变晚期非小细胞肺癌高风险特征的预后影响

2024-07-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #EGFR# #TP53#

注意了，肺癌EGFR和TP53基因双突变且基因组加倍靶向药疗效差，需要早准备替代治疗！

2024-06-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #EGFR#

JAMA子刊：难治性ctDNA RAS/BRAF野生型转移性结直肠癌获益于抗EGFR再挑战治疗

2024-05-18发表于上海

梅斯管理员 (审核中...)